mRNA expression of DOK1-6 in human breast cancer

Table 3 Downstream of tyrosine kinases (1-3) mRNA expression levels (mean ± SD)

Patient and tumour characteristics	DOK-1	P	DOK-2	P	DOK-3	P
NPI
1 vs 2	2250 ± 4652 vs 3988 ± 7824	0.48	4.37 ± 10.32 vs 4.14 ± 12.26	0.950	6802 ± 18036 vs 37024 ± 127523	0.150
1 vs 3	2250 ± 4652 vs 942 ± 1395	0.19	4.37 ± 10.32 vs 1.57 ± 4.55	0.270	6802 ± 18036 vs 9808 ± 19782	0.600
2 vs 3	3988 ± 7824 vs 942 ± 1395	0.21	4.14 ± 12.26 vs 1.57 ± 4.55	0.420	37024 ± 127523 vs 9808 ± 19782	0.210
Tumour grade
1 vs 2	1346 ± 2587 vs 3886 ± 6155	0.18	0.651 ± 1.837 vs 4.63 ± 12.49	0.190	1259 ± 2797 vs 37803 ± 126737	0.084
1 vs 3	1346 ± 2587 vs 2100 ± 5520	0.58	0.651 ± 1.837 vs 4.23 ± 10.15	0.092	1259 ± 2797 vs 8954 ± 23276	0.022
2 vs 3	3886 ± 6155 vs 2100 ± 5520	0.37	4.63 ± 12.49 vs 4.23 ± 10.15	0.910	37803 ± 126737 vs 8954 ± 23276	0.170
TNM
1 vs 2	2507 ± 4800 vs 3553 ± 7084	0.62	6.62 ± 13.46 vs 1.195 ± 3.782	0.052	26175 ± 101693 vs 4508 ± 9938	0.100
1 vs 3	2507 ± 4800 vs 0.782 ± 1.38	0.01	6.62 ± 13.46 vs 0.00562 ± 0.00942	0.015	26175 ± 101693 vs 16879 ± 39061	0.640
1 vs 4	2507 ± 4800 vs 626 ± 1252	0.11	6.62 ± 13.46 vs 0.00001 ± 0.00001	0.015	26175 ± 101693 vs 83.2 ± 80.9	0.050
2 vs 3	3553 ± 7084 vs 0.782 ± 1.38	0.07	1.195 ± 3.782 vs 0.00562 ± 0.00942	0.190	4508 ± 9938 vs 16879 ± 39061	0.440
2 vs 4	3553 ± 7084 vs 626 ± 1252	0.15	1.195 ± 3.782 vs 0.00001 ± 0.00001	0.190	4508 ± 9938 vs 83.2 ± 80.9	0.014
3 vs 4	0.782 ± 1.38 vs 626 ± 1252	0.39	0.00562 ± 0.00942 vs 0.00001 ± 0.00001	0.320	16879 ± 39061 vs 83.2 ± 80.9	0.300
Survival
DF vs LR	1839 ± 4089 vs 1957 ± 2149	0.95	3.94 ± 8.96 vs 0.00001 ± 0.00001	0.009	18203 ± 86910 vs 16027 ± 40813	0.910
DF vs DR	1839 ± 4089 vs 12051 ± 17043	0.55	3.94 ± 8.96 vs 0.00246 ± 0.00349	0.009	18203 ± 86910 vs 11083 ± 22940	0.620
DF vs DR	1839 ± 4089 vs 3023 ± 6758	0.72	3.94 ± 8.96 vs 5.93 ± 17.43	0.750	18203 ± 86910 vs 21264 ± 60618	0.880

DOK: Downstream of tyrosine kinase; NPI: Nottingham Prognostic Index; DF: Disease Free; LR: Local Recurrence; DR: Distant Recurrence.